Takeda Pharmaceutical (TAK) Accounts Payables (2017 - 2026)

Takeda Pharmaceutical has reported Accounts Payables for 10 years, with the latest figure at $2.8 billion in Q2 2026.

• On a quarterly basis, Accounts Payables fell 3.73% year-over-year to $2.8 billion in Q2 2026; TTM through Jun 2026 was $2.8 billion, a 3.73% decrease from a year earlier, with the FY2026 full-year figure at $3.1 billion, changed 0.36% from the prior year.
• Accounts Payables was $2.8 billion for Q2 2026 at Takeda Pharmaceutical, down from $3.1 billion in the prior quarter.
• The five-year high for Accounts Payables was $4.9 billion in Q1 2023, with the low at $2.7 billion in Q4 2022.
• Average Accounts Payables over 5 years is $3.2 billion, with a median of $3.0 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables soared 36.76% in 2022, then decreased 24.73% in 2024.
• Over 5 years, Accounts Payables stood at $2.7 billion in 2022, then climbed by 21.3% to $3.3 billion in 2023, then declined by 7.49% to $3.0 billion in 2024, then climbed by 0.38% to $3.0 billion in 2025, then fell by 7.74% to $2.8 billion in 2026.
• The last three Accounts Payables figures came in at $2.8 billion (Q2 2026), $3.1 billion (Q1 2026), and $3.0 billion (Q4 2025), per Business Quant data.